Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2007 2
2008 2
2009 5
2010 3
2011 5
2012 3
2013 4
2014 6
2015 10
2016 8
2017 8
2018 22
2019 20
2020 16
2021 21
2022 33
2023 31
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. Among authors: li n. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.
Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I Dr, Ghezelbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Müller FU, El-Armouche A, Tony Eissa N, Beeton C, Nattel S, Wehrens XHT, Dobrev D, Li N. Yao C, et al. Among authors: li n. Circulation. 2018 Nov 13;138(20):2227-2242. doi: 10.1161/CIRCULATIONAHA.118.035202. Circulation. 2018. PMID: 29802206 Free PMC article.
Downregulation of FKBP5 Promotes Atrial Arrhythmogenesis.
Wang X, Song J, Yuan Y, Li L, Abu-Taha I, Heijman J, Sun L, Dobrev S, Kamler M, Xie L, Wehrens XHT, Horrigan FT, Dobrev D, Li N. Wang X, et al. Among authors: li n. Circ Res. 2023 Jun 23;133(1):e1-e16. doi: 10.1161/CIRCRESAHA.122.322213. Epub 2023 May 8. Circ Res. 2023. PMID: 37154033 Free article.
Discovery of a periosteal stem cell mediating intramembranous bone formation.
Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, Li N, Liu Y, Yang YS, Eiseman M, Shim JH, Hameed M, Healey JH, Bostrom MP, Landau DA, Greenblatt MB. Debnath S, et al. Among authors: li n. Nature. 2018 Oct;562(7725):133-139. doi: 10.1038/s41586-018-0554-8. Epub 2018 Sep 24. Nature. 2018. PMID: 30250253 Free PMC article.
Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation.
Heijman J, Muna AP, Veleva T, Molina CE, Sutanto H, Tekook M, Wang Q, Abu-Taha IH, Gorka M, Künzel S, El-Armouche A, Reichenspurner H, Kamler M, Nikolaev V, Ravens U, Li N, Nattel S, Wehrens XHT, Dobrev D. Heijman J, et al. Among authors: li n. Circ Res. 2020 Sep 25;127(8):1036-1055. doi: 10.1161/CIRCRESAHA.120.316710. Epub 2020 Jul 30. Circ Res. 2020. PMID: 32762493 Free PMC article.
Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics.
Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, Xie D, Li Z, Niu X, Chen L, Yang C, Sun X, Zhou T, Su P, Li N, Greenblatt MB, Ke R, Huang J, Chen ZS, Xu R. Chen Y, et al. Among authors: li n. Adv Sci (Weinh). 2024 Feb 4:e2303752. doi: 10.1002/advs.202303752. Online ahead of print. Adv Sci (Weinh). 2024. PMID: 38311573
Based on this, most reported NPPC-markers, including Cathepsin K (Ctsk), are rare and predominantly located within the NP-outer subset. ...
Based on this, most reported NPPC-markers, including Cathepsin K (Ctsk), are rare and predominantly located within the NP-outer subse …
Rice potassium transporter OsHAK18 mediates phloem K(+) loading and redistribution.
Shen L, Fan W, Li N, Wu Q, Chen D, Luan J, Zhang G, Tian Q, Jing W, Zhang Q, Zhang W. Shen L, et al. Among authors: li n. Plant J. 2023 Oct;116(1):201-216. doi: 10.1111/tpj.16371. Epub 2023 Jul 11. Plant J. 2023. PMID: 37381632
High-affinity K(+) transporters/K(+) uptake permeases/K(+) transporters (HAK/KUP/KT) are important pathways mediating K(+) transport across cell membranes, which function in maintaining K(+) homeostasis during plant growth and stress response. . …
High-affinity K(+) transporters/K(+) uptake permeases/K(+) transporters (HAK/KUP/KT) are important pathways mediating …
A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).
Li N, Liu CF, Zhang W, Rao GW. Li N, et al. Curr Med Chem. 2023 Nov 2. doi: 10.2174/0109298673258913231019113814. Online ahead of print. Curr Med Chem. 2023. PMID: 37936461
K-Ras is a frequently mutated oncogene in human malignancies, and the development of inhibitors targeting various oncogenic K-Ras mutant proteins is a major challenge in targeted cancer therapy, especially K-Ras(G12C) is the most common mutant, which occurs i …
K-Ras is a frequently mutated oncogene in human malignancies, and the development of inhibitors targeting various oncogenic K- …
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, Nissen SE; CLEAR OUTCOMES Committees and Investigators. Ray KK, et al. Among authors: li n. Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28. doi: 10.1016/S2213-8587(23)00316-9. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061370 Free article. Clinical Trial.
195 results